This article only represents the author's own views.
Could a highly-hyped alliance between financial conglomerate Fosun and German high-tech vaccine maker BioNTech SE (BNTX.US) be the latest victim of the former’s recent debt woes?
That’s one possible takeaway from the latest disclosure by Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) that it has unloaded a big chunk of the shares it purchased in BioNTech in early 2020 when the two first announced their tie-up. We shouldn’t feel too sorry for Fosun in this case, as it profited handsomely from the investment.
您已阅读9%（584字），剩余91%（5618字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。